Teva presents positive migraine drug results

The Israeli firm has reported additional quarterly and monthly data for Ajovy, a preventive migraine treatment competing with Vyepti, which is developed and sold by Danish firm Lundbeck.

Photo: Ammar Awad/Reuters/Ritzau Scanpix

Teva Pharmaceuticals has reported additional data for its migraine drug, Ajovy, which contains the active ingredient fremanezumab. Positive results were presented at the Migraine Trust International Symposium (MTIS) in London, and later confirmed in a company press release.

In two phase III trials, entitled Halo and Focus, Ajovy in both quarterly and monthly dosing demonstrated efficacy, reducing migraine attacks by over 50% compared to a placebo in people with migraine in addition to one or more psychiatric conditions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs